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Radiolabelled compounds formulated for injection (radiopharmaceuticals), are increasingly being employed in drug
development studies. These can be used in tracer amounts for either pharmacokinetic or pharmacodynamic studies. Such
radiotracer studies can also be carried out early in man, even prior to conventional Phase I clinical testing. The aim of this
document is to describe procedures for production and safety testing of oncology radiotracers developed for imaging by
positron emission tomography in cancer patients. We propose strategies for overcoming the inability to produce compounds
in sufﬁcient quantities via the radiosynthetic routes for full chemical characterisation and toxicology testing including (i)
independent conﬁrmation as far as possible that the stable compound associated with the radiopharmaceutical is identical to
the non-labelled compound, (ii) animal toxicity studies with 510 times (typically 100 times) the intended tracer dose in
humans scaled by body surface area, and (iii) patient monitoring during the radiotracer positron emission tomography clinical
trial.
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New drug discovery methods such as computer-aided drug design
and combinatorial chemistry with high-throughput screening are
producing a large number of anticancer agents for in vivo evalua-
tion. Due to the limited resources available for developing all these
drug candidates, there is a need to efﬁciently integrate pharmaco-
kinetic and pharmacodynamic studies into pre-clinical and early
clinical testing. Early information on tumour and normal tissue
pharmacology of new agents, as well as response of tumours to
therapy with such agents will aid the rapid and rational translation
of ideas from the laboratory to the clinic. Imaging with positron
emission tomography (PET) can offer the opportunity to study
pharmacokinetics and pharmacodynamics non-invasively in
patients. PET studies involve the administration of compounds
labelled with positron-emitting isotopes (radiotracers), which have
been formulated for intravenous injection (radiopharmaceuticals).
Generally, these radiopharmaceuticals are produced at high speciﬁc
radioactivity, i.e. a high level of radioactivity is associated with a
very small amount of stable compound or carrier thus allowing
administration and detection of tracer doses of the material in
patients. Despite the opportunities provided by PET (Table 1),
there are currently no published guidelines on the safety testing
of radiopharmaceuticals prior to use in clinical trials in patients
with cancer. The primary aim of this document, therefore, is using
Cancer Research UK’s experience of this technique to propose
minimum requirements for product quality, animal toxicology
and initial clinical studies at tracer doses of PET radiopharmaceu-
ticals for oncology, which are consistent with patient safety. In
preparing this document, existing guidelines on related subjects
were taken into consideration (Begent et al, 1986, 1993; Burtles
et al, 1995; FDA, 1998; CRC/EORTC, 1999). Despite the general
considerations discussed here, each compound should be reviewed
by local, national and/or international bodies involved in medicine
control and radioactive substance administration.
Scope of this document
This document relates to studies on cancer patients only and does
not apply to studies on healthy volunteers. The procedures
described in this study apply to ‘tracer dose’ studies of novel agents
in cancer patients, which may be performed prior to conventional
Phase I trials. Tracer dose studies may include (i) pharmacokinetic
evaluation of new anticancer agents in humans by PET, and (ii)
evaluation of new PET radiotracers designed for investigating the
physiology of human tumours or providing pharmacodynamic/
mechanistic end points.
Background and experience to date
Pre-phase I studies of anticancer agents will enable tumour and
normal tissue pharmacokinetic information to be obtained prior
to Phase I clinical trials. Translational research questions that
justify a Pre-phase I study to be performed include, whether the
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www.bjcancer.comnovel agent distributes to the tumour, to what extent the agent
distributes to normal tissues and whether the metabolite proﬁles
in rodents and humans are similar. This is particularly important
for novel agents that are designed to be tumour-speciﬁc. Opportu-
nities also exist for studying pharmacokinetic modulation and
scheduling. Regarding the safety of administering tracer doses of
anticancer agents, administered radiopharmaceuticals are likely to
contain 100–1000 times less drug than the starting dose for Phase
I studies in patients (Saleem et al, 2001a). The risk to patient
volunteers is, therefore, considered to be minimal. In addition,
the amount of radioactivity administered to patients at any one
time is generally not greater than 1–3 years of annual background
radiation exposure within the UK. Cancer patients, most of them
with incurable disease, will be likely to receive cytotoxic drugs or
radiation as part of their management, which are genotoxic. It is
therefore normal practice not to consider genotoxicity as a risk
to the patient in such early protocols.
Under the auspices of Cancer Research UK, studies with carbon-
11 radiolabelled N-[2-(dimethylamino) ethyl]acridine-4-carboxa-
mide [
11C]DACA (Harte et al, 1996; Osman et al, 1997; Saleem
et al, 2001a), a topoisomerase inhibitor, established the feasibility
of performing PET studies with radiolabelled anticancer agents at
tracer doses prior to the commencement of Phase I clinical trials.
Such studies were possible because of the ability to produce radio-
pharmaceuticals with high speciﬁc radioactivities associated with
extremely small amounts (mg) of stable compound, and the inher-
ent sensitivity of PET scanning. Since pre-clinical toxicology data
and the proposed Phase I starting dose of DACA were available,
PET studies could be carried out using formulations of [
11C]DACA
containing less than 1 out of 1000 of the proposed Phase I starting
dose of DACA (18 mg m
2). This allowed studies of [
11C]DACA to
be performed in man 1 year prior to the Phase I trial (Harte et al,
1996; Osman et al, 1997; Saleem et al, 2001a). In addition to drug
distribution studies, metabolism, and in some cases, mode of
action of new compounds can be studied in man prior to the
Phase I trial. For instance, selective labelling of the methylating
agent temozolomide in the carbonyl and methyl positions has
enabled demonstration of the ring-opening of this compound in
man (Saleem et al, 2001b). Although these latter mechanistic
studies followed Phase I studies of temozolomide, it demonstrates
the potential of incorporating such strategies into early clinical
development.
Radiochemistry
Positron emitting radioisotopes, such as, carbon-11 (half-life,
20.4 min) and ﬂuorine-18 (half-life, 109.8 min) are produced using
a cyclotron. These radioisotopes are obtained from the cyclotron in
simple chemical forms. Carbon-11 is obtained as either
[
11C]carbon dioxide or [
11C]methane and ﬂuorine-18 is obtained
as either [
18F]ﬂuoride or [
18F]ﬂuorine. Radiochemistry is
performed on these simple molecules in order to incorporate them
into the compounds of clinical interest. This generally involves
several steps including conversion of the radioisotope into a reac-
tive intermediate, which is then used to radiolabel a suitable
precursor giving the radiolabelled compound of interest. The radi-
olabelled compound is then isolated using high performance liquid
chromatography (HPLC). After removal of HPLC mobile phase,
the residue is formulated and dispensed for injection under an
aseptic environment.
Compounds radiolabelled with carbon-11 or ﬂuorine-18 (via
ﬂuoride only) are produced at high speciﬁc radioactivity, i.e. a high
level of radioactivity is associated with a very small amount of the
stable compound or ‘carrier’. Although such radiolabelled
compounds are said to be ‘no carrier added’ (NCA), a sufﬁcient
amount of stable compound is usually present in the radiopharma-
ceutical after radioactive decay to allow one to obtain a mass
spectrum of the compound. For carbon-11 chemistry, the position
of incorporation of the radiolabel can be veriﬁed by carrying out
co-labelling experiments in which very small amounts of carbon-
13 labelled reagents are mixed with the carbon-11 equivalents
and used in the radiosynthesis. The puriﬁed product is then exam-
ined by carbon-13 nuclear magnetic resonance and mass
spectrometry.
Generally, synthetic strategies are designed to produce a radiola-
belled compound that is chemically identical to the compound of
clinical interest. The radiolabelled compound is puriﬁed chromato-
graphically to eliminate radiochemical and chemical by-products of
the synthesis. Unlike other non-isotopic radiolabelling strategies,
e.g., labelling of antibodies, compounds radiolabelled with
carbon-11 are chemically identical to the non-radioactive
compound. When compounds contain stable ﬂuorine then the
ﬂuorine-18-labelled version is also chemically identical, e.g. 5-
[
18F]ﬂuorouracil. Given the constraints of the short half-lives of
the radioisotopes and the limited range of labelling agents that
can be produced, it is usually not possible to use the same
synthetic route that is used in the synthesis of the non-radioactive
compound for which toxicity data would have been obtained.
Production and quality control
In most centres, radiopharmaceuticals are produced for clinical
PET studies using documented Standard Operating Procedures
(SOPS). The radiosyntheses should be performed according to
Good Manufacturing Practice (GMP) in approved production
facilities, e.g. within the UK, facilities with a Medicines Control
Agency (MCA) ‘Specials’ License for the preparation of radiophar-
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Table 1 PET radioligands and radiotracers currently being investigated/
used in oncology
Radiotracer Process studied Utility
5-[
18F]Fluorouracil Pharmacokinetics Clinical
[N-methyl-
11C]Temozolomide Pharmacokinetics Clinical
[Carbonyl-
11C]Temozolomide Pharmacokinetics Clinical
[
11C]DACA Pharmacokinetics Clinical
[
11C]BCNU Pharmacokinetics Clinical
[
13N]Cis-platinum Pharmacokinetics Clinical
[
18F]Fluorotamoxifen Pharmacokinetics Clinical
2-[
18F]Fluorodeoxyglucose Glucose utilisation Clinical
2-[
11C]Thymidine Cell proliferation Clinical
3'-[
18F]Fluorothymidine Cell proliferation Clinical
[
11C]Methionine Protein synthesis Clinical
[
11C]Leucine Protein synthesis Clinical
[
11C]Choline Choline metabolism Clinical
[
15O]H2O Perfusion & volume of distribution Clinical
[
15O]CO Blood volume Clinical
[
11C]HCO3 pH Clinical
[
11C]PK11195 Macrophage activity Clinical
16a-[
18F]Fluoro-17b-oestradiol Oestrogen receptor status Clinical
[
18F]Fluoromisonidazole Hypoxia Clinical
[
124I]FIAU Gene expression (HSV 1tk) Pre-clinical
[
18F]FHPG Gene expression (HSV1tk) Pre-clinical
[
18F]Fluoroganciclovir Gene expression (HSV1tk) Pre-clinical
[
18F]Fluoroethylspiperone Gene expression (D2-receptor) Pre-clinical
[
124I]Sodium iodide Gene expression (NaI symporter) Pre-clinical
[
11C]Daunorubicin Multi-drug resistance phenotype Pre-clinical
[
11C]Verapamil Multi-drug resistance phenotype Pre-clinical
[
124I]Annexin-V Apoptosis Pre-clinical
[
124I]VG76e VEGF levels Pre-clinical
[
124I]uPA ligand uPA receptor status Pre-clinical
[
124I]FTI ligand Farnesyl transferase activity Pre-clinical
[
124I]c-ErbB2 antibody c-ErbB2 receptor status Pre-clinical
DACA, N-[2-(Dimethylamino)ethyl]-acridine-4-carboxamide; BCNU, Bis-chloro-
ethylnitrosourea; FIAU, 5-[
124I]iodo-2-'-fluoro-1b-D-arabinofuranosyluracil; FHPG,
9-(1-[
18F]ﬂuoro-3-hydroxy-3-propoxy) methylguanine; uPA, urokinase plasminogen
activator; FTI, farnesyl transferase inhibitor.
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countries such as the US Food and Drug Administration (FDA)
in North America are responsible for issuing guidance notes and
regulations. Due to the short half-life of the positron emitters,
fewer Quality Control tests can be carried out on radiopharmaceu-
ticals before their release for clinical studies. Thus, the continuous
assessment of the effectiveness of the Quality Assurance system
before initiation of the Pre-phase study is very important. This
requires compliance with the relevant rules and guidance for phar-
maceutical manufacture and distribution. In accordance with the
UK MCA guidance, for instance, dispensing of radiopharmaceuti-
cals should be carried out in Class I isolators and a record of
trained personnel who perform various activities should be kept
to comply with GMP. Production of different radioactive products
in the same work stations (‘hot cells’) and at the same time should
be avoided in order to minimise the risk of cross-contamination or
mix-up. Process validation, in-process controls and monitoring of
process parameters and environment assume particular importance
in cases where it is necessary to take decisions to release or reject a
batch or product before all tests are completed (MCA, 1997).
Formulated samples (usually for intravenous administration) are
subjected to in-house independent Quality Control procedures
and must meet deﬁned speciﬁcations, which include chemical
and radiochemical purities with set limits on stable compound
and impurities. These limits are set by production chemists, Qual-
ity Control team, biologists and clinical investigators based on
radiosynthesis, analytical methodology, limit of detection of the
stable compound and impurities, purity proﬁle, nature of impuri-
ties, effect of stable compound on tracer kinetics and study type.
These limits should be reviewed as new data become available. In
addition, analysis of residual organic solvents, e.g., acetonitrile, in
the radiopharmaceutical should be carried out and must meet
deﬁned speciﬁcations (EMEA, 1998). Furthermore, steps must be
taken to ensure that samples are sterile, isotonic, apyrogenic and
have a suitable pH. Currently, a monograph for PET oncology
radiopharmaceuticals is only available for 2-[
18F]ﬂuorodeoxyglu-
cose (EP, 1996). Examples of radiochemical and chemical purities
of radiopharmaceuticals for PET oncology recently analysed by
the independent Quality Control team within the authors’ own
laboratories are shown in Table 2. Radiopharmaceuticals having
very high speciﬁc radioactivity often undergo decomposition due
to radiolysis because of the high speciﬁc activity per se and the
need to start the synthesis with very high quality radioactivity. It
is, therefore, recommended practice to evaluate the stability of
the radiopharmaceutical during test runs for up to 4 h (for
carbon-11 and ﬂuorine-18) after radiosynthesis, to assure that no
radiochemical or chemical changes have occurred.
Toxicology
Since Pre-phase-1 studies may involve the ﬁrst time administra-
tion of a compound to humans, there is the need to establish
general procedures for pre-clinical toxicology testing of these
radiopharmaceuticals, despite the very low dose of drug required
for detection by ‘tracer’ PET. Given the low levels of radiolabelled
compound required and the limited number of doses each patient
will receive (typically 1), it is recommended that single-dose toxi-
cology studies of the radiopharmaceutical in the formulation to be
used in the tracer studies in man are performed. If multiple dose
studies are carried out, the radiopharmaceutical is administered
weeks apart and, from a toxicological stand-point, is, therefore,
considered equivalent to a single dose. Due to differences in
synthetic routes, impurity proﬁles and occasionally, vehicle used
in formulation of radiopharmaceuticals, the toxicology studies
should be done even if other (non-radiopharmaceutical) toxicol-
ogy data are available. As the trials are to be carried out in
cancer patients with limited life expectancy, long-term repeat dose
toxicology, genotoxicity and carcinogenicity studies may usually
be omitted, but should be considered on a case by case basis.
Biodistribution studies after a single injection of the radiopharma-
ceutical should be performed to determine the dosimetry. With
regards to impurities generated during the radiosynthesis, it
should be emphasised that the parent compound will be given
at only tracer doses, and hence exposure to minor impurities
would be negligible. They should, however, still be considered
and limits set. Due consideration should also be given to levels
of the other components in the formulation, such as anti-oxidants
and residual solvents. Also of importance is the issue of immuno-
genicity. If PET radiopharmaceuticals are to be given more than
once to the same patient then there is the theoretical risk of
hypersensitivity. As with normal pharmaceuticals, this issue should
be addressed by inspecting the structures of compounds for any
possible alerts for immunogenicity by analogy with related
compounds, e.g., peptides in general or the presence of a penicil-
loic acid moiety. Expert advice should be obtained if potentially
immunogenic compounds are encountered. In addition to animal
toxicology, patients should be monitored for toxicity as with stan-
dard Phase I studies, and the patient studies should be performed
in accordance with the guidelines for Good Clinical Practice
(GCP) (ICH, 1996).
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Table 2 Chemical analysis and set limits on oncology radiopharmaceuticals recently analysed by the Quality Control
team at the author’s instituion. All samples were analysed by reversed-phase HPLC with UV detection except for 2-
[
18F]ﬂuorodeoxyglucose (2-[
18F]FDG) which was analysed by ion-exchange HPLC with pulsed-amperometric detection
Injected
a Stable
Chemical impurities Radiochemical
Radio- radioactivity compound Precursor
b Unidentiﬁed Purity Impurity
pharmaceutical (MBq) (mg) (mg) (mg) (%) (%)
[
11C]Temozolomide 226.81 1.26
c 0.04 0.02 99.05 0.95
(10.0) (1.0) (1.0) (95.0) (5.0)
[
18F]Fluorouracil 344.66 1235.62
d 476.70 6.89 98.84 1.16
(1750–2000) (51500) (550) (98.0) (2.0)
[
11C]DACA 472.70 25.54 2.31 0.63 95.36 4.64
(35.0) (5.0) (5.0) (95.0) (5.0)
2-[
11C]Thymidine 373.96 5.09 0.00 0.00 98.86 1.14
(5.0) (95.0) (5.0)
2-[
18F]FDG 168.72 0.00 9.73 0.00 99.99 0.01
N/A (500) N/A (95.0) (5.0)
aAll data are for a single patient dose.
bImpurities from the precursor used for radiolabelling (diazo-5-imidazole-4-carboxamide, uracil,
desmethyl DACA and glucose for temozolomide, ﬂuorouracil, DACA, thymidine, and FDG, respectively).
cMean values for 10 most
recent analyses, with limit values for each parameter given below in parenthesis.
d‘Carrier-added’ synthesis. [
11C]DACA, [
11C]N-[2-
(Dimethylamino)ethyl]-acridine-4-carboxamide; 2-[
18F]FDG, 2-[
18F]ﬂuorodeoxyglucose; N/A, not applicable.
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Following a meeting of a Cancer Research UK expert committee on
PET Pre-phase I trials, a number of recommended procedures were
developed. These recommendations will be reviewed in the next 5-
years as more data become available. It is recommended that the
following studies should be performed for candidate compounds:
(1) Chemical identity and purity, (2) Animal toxicology, (3) Clin-
ical trial.
(1) Chemical identity and purity
The major requirement should be to provide evidence that the
radiopharmaceutical prepared via the radiosynthetic route is iden-
tical to the non-radiolabelled reference compound. If the
radiosynthetic route differs from that for the non-radiolabelled
compound then the radiosynthetic route should be documented
and be available for review by an independent body. The chemical
identity of the radiolabelled compound after decay should be
determined by mass spectrometry and nuclear magnetic resonance
methods if feasible. Furthermore, radiochemical purity, radionucli-
dic purity, and chemical purity of the radiopharmaceutical should
be determined and documented. Radiochemical and chemical
impurities may be identiﬁed by HPLC-UV and HPLC-mass spec-
trometry methods. In general, the procedure used will depend on
the chemical structure and radiosynthesis used to produce the
compound. Once a radiosynthesis has been developed, it is
normal practice to perform a number of runs (3–5) to demon-
strate the robustness and reproducibility of the manufacturing
process and prove that the radiopharmaceutical is pure, sterile,
isotonic, apyrogenic, stable and of suitable pH. The trial runs also
ensure that the total radioactivity, speciﬁc radioactivity and radio-
chemical purity are appropriate for the clinical study. Batch
manufacturing records of the radiosynthesis and quality control
analyses should be documented and be available for inspection.
Since the radiosynthetic route may differ from that for the non-
radiolabelled compound, the product may contain impurities,
which have not been subjected to safety evaluation. Before any
material is made for clinical use, limits on the amounts of iden-
tiﬁed and unidentiﬁed impurities should be set on a case by case
basis. A standard operating procedure (SOP) should be prepared
for production of future batches. This must be done before the
radiopharmaceutical can be administered to man. Due to the
difﬁculty in performing extensive tests on each patient dose
(batch) produced, it is not usual practice to obtain a certiﬁcate
of analysis. Instead, a formal recorded decision must be taken
by the Qualiﬁed Person (Quality Control ofﬁcer) on the confor-
mity of the batch to ensure that they meet the pre-deﬁned
standards speciﬁed in the SOP.
(2) Animal toxicology
Toxicology and biodistribution studies are designed to ensure that
the radiopharmaceutical is non-toxic from a chemical and radia-
tion viewpoint at the doses to be administered to patients. Any
previous animal toxicology data on the compound should be docu-
mented and used in designing the Pre-phase I study. The studies
should be performed under the highest quality standards possible
(equivalent to GLP). The following recommendations should be
adhered to:
Investigator The principal investigator should have expertise in
pre-clinical toxicology testing. Alternatively, the toxicology work
may be subcontracted to a certiﬁed commercial establishment.
Protocol A protocol for the toxicology studies should be
prepared and documented.
Chemical toxicity The radiopharmaceutical (after radioactive
decay) formulated in the recommended vehicle should be used.
The radiopharmaceutical should be administered as a single dose
equal to at least 10 times (and typically 100 times) the intended
tracer dose in humans (scaled by body surface area). The intended
tracer dose in humans is the total amount (in mg) of the stable
compound (associated with the desired level of radioactivity in
MBq) that will be administered to a patient. The total patient dose
is usually of the order of 1–30 mg for ‘non-carrier added synthesis’
(Table 2). Thus, the dose is selected based on the achievable radio-
synthetic yield. The recommended route for clinical administration
(usually intravenous) should be used. Aliquots of dosing solutions
should be analysed for drug content by HPLC-UV, gas chromato-
graphy-mass spectrometry, liquid chromatography-mass spectro-
metry or other sensitive analytical methods. Toxicology studies in
one species is adequate (mouse or rat; male unless there is a reason
to use females). Three to ﬁve animals should be treated with vehi-
cle only (controls) and 3–5 animals should be treated with the
drug. Animals should be monitored for 14 days for death, changes
in body weight, and clinical signs (e.g., neurological, gastrointest-
inal, performance status, hair characteristics, feeding status,
lacrymation, and urine colouration). Animals should be killed on
day 14 after the above examinations and macroscopic pathology
evaluated. If possible, clinical chemistry and haematology analyses
should be carried out, but histopathology, genotoxicity and carci-
nogenicity studies are not required unless clearly indicated.
Reproductive toxicology studies are not required as long as patients
of reproductive age will be advised to take appropriate precautions
to avoid pregnancy, and pregnant and lactating patients will be
excluded from any clinical studies. A full toxicology study (maxi-
mum tolerated/administrable dose endpoint; 7-day repeat) would
be required if signiﬁcant weight loss ensues or if any of the obser-
vational endpoints mentioned above are encountered. A full
toxicology study would also be required if the 10-100X tracer dose
for the non-radioactive compound used in the toxicology studies is
greater than 10% of the maximum tolerated dose (if this is known)
or the effective therapeutic dose (if the MTD is not known) in the
same species.
Radiation toxicity Dosimetry studies should be performed with
the radiopharmaceutical in rodents (usually adult male/female rats)
over several time points depending on the biological and physical
half-lives of the radioisotope. The radioactivity in blood, urine
and tissues (gonads, bone marrow, colon, lung, stomach, bladder,
breast, liver, oesophagus, thyroid, skin, bone surface, adrenals,
brain, upper large intestine, small intestine, kidney, muscle,
pancreas, spleen, thymus, uterus, heart and eye), expressed as a
percentage of injected radioactivity should be determined to enable
calculation of the effective radiation dose (mSv) to each tissue. In
the UK, the effective dose is required by the Administration of
Radioactive Substances Advisory Committee (ARSAC).
(3) Clinical trial
As for all clinical trials, the details of the objectives, patient eligibil-
ity, treatment schedules, endpoints and all tests should be
documented in the clinical trial protocol. This, along with the
patient information-sheet must be submitted to the local hospital
research ethics committee (LREC). Regulatory approval for the trial
must be obtained from the appropriate Regulatory Authority. In
the UK, this is the Medicines Control Agency and for academic
studies an application for a Doctor and Dentist’s Exemption
(DDX) would be made, although this is likely to change with the
implementation of the European Clinical Trials Directive. The
protocol should deﬁne all the tests to be performed on the patients.
Although patients will only receive a tracer dose of drug and no
toxicity is expected, all patients must be monitored for safety (side
effects) for up to 24 h after dosing. Tests should include ECG,
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The protocol will deﬁne the eligibility criteria for participation in
the trial. As for all trials of novel agents, pregnant and lactating
women should be excluded and patients of reproductive age should
use adequate contraception for the duration of the study.
ARSAC Within the UK, a certiﬁcate for the administration of
radioactive medicinal products under the Medicines Act 1968
and the Medicines (Administration of Radioactive Substances)
Regulations 1978 must be obtained by the principal investigator
from ARSAC prior to patient studies (ARSAC, 1998). This is a
certiﬁcate of limited validity that allows speciﬁc radiolabelled
compounds of pre-deﬁned effective dose to be administered to
cancer patients (also for normal volunteers and other condi-
tions).
In summary, Pre-phase I studies will enable pharmacokinetic
and pharmacodynamic studies to be carried out early in the clinical
development of an anticancer agent providing added value to the
development of the drug. The procedures proposed describe mini-
mal toxicology studies consistent with safe use to enable PET
studies to be carried out safely and in a timely fashion. The key
components introduced in this document are the proposed strate-
gies for overcoming the inability to produce compounds in
sufﬁcient quantities via the radiosynthetic routes for full chemical
characterisation and toxicology testing. Speciﬁcally, these are:
. to independently conﬁrm as far as possible that the stable com-
pound associated with the radiopharmaceutical is identical to the
non-radiolabelled compound.
. to perform animal toxicity studies at 510 times (typically 100
times) the intended tracer dose in humans (scaled to body sur-
face area).
. to undertake careful monitoring of patients during the tracer
PET studies.
The proposed procedures are based on strategies given earliear.
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